Cellular uptake and interaction with purified membranes of rebeccamycin derivatives

European Journal of Pharmacology

Volumn 389, Issue 2-3, 2000, Pages 141-146

  Goossens, Jean François ^a   Hénichart, Jean Pierre ^b   Anizon, Fabrice ^c   Prudhomme, Michelle ^c   Dugave, Christophe ^d   Riou, Jean François ^e   Bailly, Christian ^f  

^a UNIV LILLE   (France)

^b Lab Biomaths METRICS   (France)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

^d CEA SACLAY   (France)

^e SANOFI   (France)

^f INSERM   (France)

Author keywords

Carbohydrate; Cell membrane; Cellular uptake; Indolocarbazole; Rebeccamycin

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; CAMPTOTHECIN; CARBAZOLE DERIVATIVE; REBECCAMYCIN;

ANIMAL CELL; ARTICLE; CELL STRAIN HL 60; DRUG UPTAKE; HUMAN; HUMAN CELL; LEUKEMIA P 388; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; CARBAZOLES; CELL MEMBRANE; HL-60 CELLS; HUMANS; INDOLES; TUMOR CELLS, CULTURED;

EID: 0034681374     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00895-X     Document Type: Article

References (22)

1. Anizon F., Belin L., Moreau P., Sancelme M., Voldoire A., Prudhomme M., Ollier M., Sevère D., Riou J.F., Bailly C., Fabro D., Meyer T. Syntheses and biological activity (topoisomerases inhibition, antitumoral and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group. J. Med. Chem. 40:1997;3456-3465.
2. Arakawa H., Iguchi T., Morita M., Yoshinari T., Kojiri K., Suda H., Okura A., Nishimura S. Novel indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(β-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo-[3,4-c]carbazole-5,7-(6H)-dione (NB-506): its potent antitumor activities in mice. Cancer Res. 55:1995;1316-1320.
3. Bailly C., Carrasco C., Hamy F., Vezin H., Prudhomme M., Saleem A., Rubin E. The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. Biochemistry. 38:1999;8605-8611.
4. Bailly C., Colson P., Houssier C., Rodrigues-Pereira E., Prudhomme M., Waring M.J. Recognition of specific sequences in DNA by a topoisomerase I inhibitor derived from the antitumor drug rebeccamycin. Mol. Pharmacol. 53:1998;77-87.
5. Bailly C., Qu X., Graves D.E., Chaires J.B. Calories from carbohydrates. Energetic contribution of the carbohydrate moiety of rebeccamycin to DNA binding and the effect of its orientation on topoisomerase I inhibition. Chem. Biol. 6:1999;277-286.
6. Bailly C., Riou J.F., Colson P., Houssier C., Rodrigues-Pereira E., Prudhomme M. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin. Biochemistry. 36:1997;3917-3929.
7. Burns C.P., Haugstad B.N., North J.A. Membrane transport of mitoxantrone by L1210 leukemia cells. Biochem. Pharmacol. 36:1987;857-860.
8. Casieri M.A., Ber E., Fong T.M., Sadowski S., Bansal A., Swain C., Saward E., Frances B., Burns D., Strader C.D. Characterization of the binding of a potent, selective, radioiodinated antagonist to the human neurokinin-1 receptor. Mol. Pharmacol. 42:1992;458-463.
9. Labourier E., Riou J.F., Prudhomme M., Carrasco C., Bailly C., Tazi J. Poisoning of topoisomerase I by an antitumor indolocarbazole drug: stabilization of topoisomerase I-DNA covalent complexes and specific inhibition of the protein kinase activity. Cancer Res. 59:1999;52-55.
10. Madelaine J., Prost S., Naudin A., Riou G., Lavelle F., Riou J.F. Sequential modifications of topoisomerase I activity in a camptothecin resistant cell line established by progressive adaptation. Biochem. Pharmacol. 45:1993;339-348.
11. Moreau P., Anizon F., Sancelme M., Prudhomme M., Bailly C., Carrasco C., Ollier M., Sevère D., Riou J.F., Fabro D., Meyer T., Aubertin A.M. Syntheses and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide heterocycle. J. Med. Chem. 41:1998;1631-1640.
12. Moreau P., Anizon F., Sancelme M., Prudhomme M., Bailly C., Ollier M., Sevère D., Riou J.F., Fabbro D., Meyer T., Aubertin A.M. Syntheses and biological activities of rebeccamycin analogues. Introduction of a halogenoacetyl substituent. J. Med. Chem. 42:1999;584-592.
13. Moreau P., Anizon F., Sancelme M., Prudhomme M., Sevère D., Riou J.F., Goossens J.F., Hénichart J.P., Bailly C., Labourier E., Tazi J., Fabbro D., Meyer T., Aubertin A.M. Synthesis, mode of action and biological activities of rebeccamycin bromo-derivatives. J. Med. Chem. 42:1999;1816-1822.
14. Morgan J.S., Creasey D.C., Wright J.A. Evidence that the antitumor agent hydroxyurea enters mammalian cells by a diffusion mechanism. Biochem. Biophys. Res. Commun. 134:1986;1254-1259.
15. Ohe Y., Tanigawara Y., Fujii H., Ohtsu T., Wakita H., Igarashi T., Minami H., Eguchi K., Shinkai T., Tamura T., Kunotoh H., Saijo N., Okada K., Ogino H., Sasaki Y. Phase I and pharmacology study of 5-day infusion of NB-506. Proc. ACSO. 16:1997;199a.
16. Pindur U., Kim Y.-S., Mehrabani F. Advances in indolo[2,3-a]carbazole chemistry: design synthesis of protein kinase C and topoisomerase I inhibitors. Curr. Med. Chem. 6:1999;29-69.
17. Prudhomme M. Indolocarbazoles as anti-cancer agents. Curr. Pharm. Des. 3:1997;265-290.
18. Rodrigues-Pereira E., Belin L., Sancelme M., Prudhomme M., Ollier M., Rapp M., Servère D., Riou J.F., Fabbro D. Structure-activity relationships in a series of substituted indolocarbazoles: topoisomerase I and protein kinase C inhibition and antitumoral and antimicrobial properties. J. Med. Chem. 39:1996;4471-4477.
19. Saijo N. New chemotherapeutic agents for the treatment of non-small cell lung cancer. Chest. 113:1998;17S-23S.
20. Yamashita Y., Fujii N., Murakata C., Ashizawa T., Okabe M., Nakano H. Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives. Biochemistry. 31:1992;12069-12075.
21. Yoshinari T., Matsumoto M., Arakawa H., Okada H., Noguchi K., Suda H., Okura A., Nishimura S. Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(β-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo-[3,4-c]carbazole-5,7-(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity. Cancer Res. 55:1995;1310-1315.
22. Yoshinari T., Yamada A., Uemura D., Nomura K., Arakawa H., Kojiri K., Yoshida E., Suda H., Okura A. Induction of topoisomerase I-mediated DNA cleavage by a new indolocarbazole, ED-110. Cancer Res. 53:1993;490-494.